Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Per 320/12.5 mg tab Valsartan 320 mg, hydrochlorothiazide 12.5 mg.
Indication
2nd-line treatment of HTN in patients whose BP is inadequately controlled by monotherapy.
Instruction
May be taken with or without food.
Drug interaction
Increased incidence of hypotension, hyperkalemia & changes in renal function w/ ACE inhibitors, aliskiren. Increased K levels w/ K-sparing diuretics or K supplements, K-containing salt substitutes, drugs increasing K levels eg, heparin. Increased systemic exposure to valsartan w/ rifampin, ciclosporin, ritonavir. Increased lithium conc & toxicity. Drugs causing hypokalemia eg, corticosteroids, ACTH, amphotericin, penicillin G, carbenoxolone, antiarrhythmics. Monitor serum electrolyte balance w/ antidepressants, antipsychotics, antiepileptics. Decreased antihypertensive effects w/ NSAIDs. Electrolyte imbalance w/ digitalis glycosides. Combination w/ antihypertensives; insulin, oral antidiabetic agents; anionic exchange resins, allopurinol, amantadine, diazoxide, cytotoxic drugs, anticholinergic agents, vit D, Ca salts, methyldopa, noradrenaline, barbiturates, narcotics, alcohol.
Malaysia
